More Evidence Favors PCSK9 as a Target in Lipid Management

A new PCSK9 inhibitor — the monoclonal antibody AMG 145 — helps reduce LDL levels in patients with dyslipidemia, according to two studies presented at the American Heart Association meeting and published in the Lancet. PCSK9 is an enzyme that blocks clearance of LDL cholesterol and has been getting increased attention as a target in lipid management.

The phase II studies, conducted by AMG 145's manufacturer, examined the drug's effects in patients with LDL levels above 86 mg/dL. In one study, patients taking statins plus AMG 145 showed a roughly 50% LDL reduction versus those taking statins plus placebo. In the other, with AMG 145 as monotherapy, active treatment achieved similar LDL reductions. The results were similar to those observed with another PCSK9 inhibitor, SAR236553.

The New York Times reports that at least one manufacturer of a PCSK9 inhibitor has announced the start of a phase III trial.